David A. Spellman
Net Worth
Last updated:
What is David A. Spellman net worth?
The estimated net worth of Mr. David A. Spellman is at least $3,828,517 as of 16 May 2023. He owns shares worth $1,366,238 as insider, has earned $98,039 from insider trading and has received compensation worth at least $2,364,240 in Akebia Therapeutics, Inc..
What is the salary of David A. Spellman?
Mr. David A. Spellman salary is $591,060 per year as Senior Vice President, Chief Financial Officer & Treasurer in Akebia Therapeutics, Inc..
How old is David A. Spellman?
Mr. David A. Spellman is 48 years old, born in 1977.
What stocks does David A. Spellman currently own?
As insider, Mr. David A. Spellman owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Akebia Therapeutics, Inc. (AKBA) | Senior Vice President, Chief Financial Officer & Treasurer | 446,483 | $3.06 | $1,366,238 |
What does Akebia Therapeutics, Inc. do?
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. Akebia Therapeutics, Inc. has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, the European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
David A. Spellman insider trading
Akebia Therapeutics, Inc.
Mr. David A. Spellman has made 7 insider trades between 2021-2023, according to the Form 4 filled with the SEC. Most recently he sold 63,567 units of AKBA stock worth $67,890 on 16 May 2023.
The largest trade he's ever made was exercising 63,567 units of AKBA stock on 16 May 2023. As of 16 May 2023 he still owns at least 446,483 units of AKBA stock.
Akebia Therapeutics key executives
Akebia Therapeutics, Inc. executives and other stock owners filed with the SEC:
- Dr. Steven Keith Burke (64) Senior Vice President of R&D and Chief Medical Officer
- Mr. David A. Spellman (48) Senior Vice President, Chief Financial Officer & Treasurer
- Mr. Dell Faulkingham (52) Senior Vice President & Chief Commercial Officer
- Mr. Jason A. Amello (57) Executive Officer
- Mr. John P. Butler MBA (61) Chief Executive Officer, Pres & Director
- Mr. Michel Dahan (46) Senior Vice President & Chief Operating Officer